U.S. Stock Market Midday Update: Strata Skin Sciences up 41.18%

U.S. Stock Market Midday Update Strata Skin Sciences rose 41.18%. According to recent key news: On September 22, the International Journal of Dermatology published a randomized controlled combination trial initiated by researchers, confirming its superiority over monotherapy. This result has driven sustained market growth and expanded the range of indications, leading to a significant increase in Strata Skin Sciences' stock price. Market growth and expanded indications. Stocks with High Trading Volume in the Industry Intuitive Surgical rose 0.17%, with a trading volume of $102 million. According to recent key news: On September 23, Intuitive Surgical achieved an annualized return of 19.12% over the past 15 years, outperforming the market by 6.67%. Its current market capitalization is $159.36 billion. This news boosted investor confidence, driving the stock price up. On September 21, analysts believe that Intuitive Surgical's fundamentals remain strong and recommend buying on price pullbacks. This view attracted some investors, leading to a slight increase in the stock price. On September 20, although Intuitive Surgical was rated as "Moderate Buy," top analysts believe there are five stocks that are more worthy of purchase. This news had a limited impact on the stock price. The medical device industry is performing steadily overall, with significant capital inflows. Boston Scientific fell 0.34%. According to recent key news: On September 22, Boston Scientific experienced a consecutive 10-day decline, setting a record for the longest losing streak in history, with a stock price drop of 10.63%, marking the longest losing streak since 1992, raising concerns about its future performance. Data source: Dow Jones Market Data, FactSet. On September 23, analyst Steed gave Boston Scientific a strong buy rating, with a target price of $125.85, indicating a 29.70% upside potential from current levels, reflecting a positive market outlook on its future performance. Data source: TipRanks. On September 19, Needham reiterated a buy rating with a target price of $121.00, further supporting the market's positive expectations for Boston Scientific. Data source: TipRanks. The medical industry has shown volatility recently and requires attention. Abbott fell 0.02%, with increased trading volume. According to recent important news: On September 22, Abbott's FreeStyle Libre business is considered a strong driver of the company's long-term growth. The company's diversified operations in pharmaceuticals, diagnostic devices, and nutrition further enhance its operational capabilities. Abbott has gained a competitive advantage due to its strong foundation in healthcare and thousands of patents, giving it some pricing power. On September 21, market analysis shows that although Abbott was rated as "Moderate Buy," top analysts believe there are five stocks that are more worthy of purchase, which may have affected investor confidence in Abbott On September 20th, market analysis indicated that Abbott was not included in the list of the top five stocks recommended by leading analysts, which may lead to concerns about its future performance. The healthcare industry has significant long-term growth potential. Stocks ranked among the top in industry market capitalization Stryker fell 0.04%. According to recent key news: On September 23rd, MarketBeat's analysis showed that although Stryker was rated as "Moderate Buy," top analysts believe there are five stocks that are more worthy of purchase. This news may weaken investor confidence in Stryker, affecting its stock price. On September 22nd, MarketBeat reiterated that Stryker was not included in the list of the top five stocks recommended by leading analysts, which may further exacerbate market concerns about its future performance. On September 20th, MarketBeat's report pointed out that Stryker failed to make it onto the analyst-recommended stock list, which may negatively impact investor sentiment. Market confidence in Stryker has weakened